PSSR yields 800.00% · ABBV yields 3.06%● Live data
📍 PSSR pulled ahead of the other in Year 1
Combined, PSSR + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PSSR + ABBV for your $10,000?
PASSUR Aerospace, Inc., a business intelligence company, provides predictive analytics and decision support technology for the aviation industry in the United States and internationally. The company's products, include ARiVAT EMPO, a dynamic gate-to-gate global flight tracking; ARiVA AWARE that provides continuous forecasts and alerts to achieve the most efficient execution of the daily operation; and ARiVA WORKFLOW, an integrated communication and collaboration on shared workflow platform to maximize use of existing assets and capacity. Its products also comprise ARiVA INTEL Data, a reporting and analytical tool that enable insights into operational performance to drive continuous improvement; ARIVA BIZAV, a complete set of tools to help forecast and manage the operation; ARIVA LFM, which ensures various landing fees and related charges are being fully and accurately captured and billed; and ARiVA STRATEGY that integrates commercial strategies and operational priorities. It serves airlines and airports. PASSUR Aerospace, Inc. was founded in 1967 and is headquartered in Stamford, Connecticut.
Full PSSR Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.